Answers are grounded in this paper and cite their sources.
Background/Aims To evaluate the association between systemic oral corticosteroid use and incident glaucoma and glaucoma suspect among patients with systemic lupus erythematosus (SLE). Methods This retrospective, nationwide, population-based cohort study included 1066 steroid-naïve patients with newly diagnosed SLE and no baseline glaucoma identified from the Korean National Health Insurance Service database (2008–2022). Oral corticosteroid exposure after SLE diagnosis was identified from reimbursement claims and converted to prednisolone-equivalent doses and was assessed by total prescription duration, mean daily dose and cumulative dose. Incident glaucoma and glaucoma suspect were identified using diagnostic codes. Cox proportional hazards models were used to estimate adjusted HRs and 95% CIs. Results Over 10 220 person-years of follow-up, 111 patients developed glaucoma and 367 developed glaucoma suspect. Compared with <180 days of corticosteroid use, prolonged use (≥180 days) was associated with higher risks of glaucoma (adjusted HR 1.96; 95% CI 1.06 to 3.63) and glaucoma suspect (adjusted HR 1.50; 95% CI 1.08 to 2.10). Sustained corticosteroid therapy was the exposure pattern most consistently associated with glaucoma and glaucoma suspect, whereas mean daily dose showed no clear monotonic dose-response pattern and very long-term treatment did not confer additional risk. Conclusions In this nationwide SLE cohort, sustained oral corticosteroid therapy was associated with glaucoma and glaucoma suspect. Although the extent to which these associations reflect corticosteroid exposure itself vs underlying SLE disease and treatment burden could not be determined, sustained oral corticosteroid exposure may help identify patients at higher risk of subsequent glaucoma.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: